Identification

Name
Nitrendipine
Accession Number
DB01054  (APRD00421)
Type
Small Molecule
Groups
Approved, Investigational
Description

A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive. [PubChem]

Structure
Thumb
Synonyms
  • 1,4-dihydro-2,6-Dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid ethyl methyl ester
  • BAY e 5009
  • Bayotensin
  • Baypress
  • Bylotensin
  • Deiten
  • Nidrel
  • Nitrendipino
  • Nitrendipinum
International/Other Brands
Bayotensin / Baypress / Deiten / Nidrel / Nitrepin / Nitrezic
Categories
UNII
9B627AW319
CAS number
39562-70-4
Weight
Average: 360.3612
Monoisotopic: 360.132136382
Chemical Formula
C18H20N2O6
InChI Key
PVHUJELLJLJGLN-UHFFFAOYSA-N
InChI
InChI=1S/C18H20N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9,16,19H,5H2,1-4H3
IUPAC Name
3-ethyl 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC

Pharmacology

Indication

For the treatment of mild to moderate hypertension

Pharmacodynamics

Nitrendipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Nitrendipine is similar to other peripheral vasodilators. Nitrendipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

Mechanism of action

By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Nitrendipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

TargetActionsOrganism
AVoltage-dependent L-type calcium channel subunit alpha-1C
inhibitor
Human
AVoltage-dependent calcium channel subunit alpha-2/delta-1
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit beta-2
inhibitor
Human
AVoltage-dependent calcium channel gamma-1 subunit
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1D
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1S
inhibitor
Human
UVoltage-dependent calcium channel subunit alpha-2/delta-2
inhibitor
Human
UVoltage-dependent T-type calcium channel subunit alpha-1H
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

> 99%

Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Nitrendipine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbafunginThe therapeutic efficacy of Abafungin can be increased when used in combination with Nitrendipine.Investigational
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Nitrendipine.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Nitrendipine.Approved, Investigational
AceclofenacThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Nitrendipine.Approved, Vet Approved
Acetylsalicylic acidThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Nitrendipine.Approved
AlbaconazoleThe therapeutic efficacy of Albaconazole can be increased when used in combination with Nitrendipine.Investigational
AlclofenacThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlcuroniumNitrendipine may increase the neuromuscular blocking activities of Alcuronium.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Aldesleukin.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Nitrendipine.Experimental, Investigational
AlfuzosinAlfuzosin may increase the hypotensive activities of Nitrendipine.Approved, Investigational
AliskirenNitrendipine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Nitrendipine.Approved, Investigational
AlminoprofenThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Alminoprofen.Experimental
AlprenololNitrendipine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Nitrendipine.Approved, Investigational
AmifostineNitrendipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Amiloride.Approved
AminophenazoneThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Aminophenazone.Approved, Withdrawn
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Nitrendipine.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Nitrendipine.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Nitrendipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Nitrendipine.Approved, Illicit
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Nitrendipine.Approved
Amphotericin BNitrendipine may decrease the nephrotoxic activities of Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Nitrendipine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Amyl Nitrite.Approved
AntipyrineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Antipyrine.Approved, Investigational
AntrafenineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Antrafenine.Approved
ApalutamideThe serum concentration of Nitrendipine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Nitrendipine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Nitrendipine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Nitrendipine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Nitrendipine.Approved, Investigational
ArotinololThe risk or severity of hypotension can be increased when Arotinolol is combined with Nitrendipine.Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Nitrendipine.Approved, Investigational
Ascorbic acidThe serum concentration of Ascorbic acid can be increased when it is combined with Nitrendipine.Approved, Nutraceutical
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Nitrendipine.Approved
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Nitrendipine.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Nitrendipine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Nitrendipine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Nitrendipine.Approved
AtracuriumNitrendipine may increase the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateNitrendipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AvanafilAvanafil may increase the antihypertensive activities of Nitrendipine.Approved
AvatrombopagThe serum concentration of Avatrombopag can be increased when it is combined with Nitrendipine.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Nitrendipine.Approved, Investigational
AzapropazoneThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Azapropazone.Withdrawn
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Azilsartan medoxomil.Approved, Investigational
BalsalazideThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Nitrendipine.Experimental
BarbitalBarbital may increase the hypotensive activities of Nitrendipine.Illicit
BaricitinibThe serum concentration of Baricitinib can be increased when it is combined with Nitrendipine.Approved, Investigational
BarnidipineNitrendipine may increase the antihypertensive activities of Barnidipine.Approved
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Nitrendipine.Approved, Investigational
BenazeprilBenazepril may increase the hypotensive activities of Nitrendipine.Approved, Investigational
BenazeprilatNitrendipine may increase the hypotensive activities of Benazeprilat.Experimental
BendazacThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Bendazac.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Nitrendipine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Nitrendipine.Withdrawn
BenorilateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzydamineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Benzydamine.Approved
BepridilNitrendipine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Nitrendipine.Approved, Vet Approved
BetaxololBetaxolol may increase the hypotensive activities of Nitrendipine.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Nitrendipine.Approved
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Nitrendipine.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Nitrendipine.Experimental
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Nitrendipine.Approved, Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Nitrendipine.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Nitrendipine.Approved
BisoprololBisoprolol may increase the hypotensive activities of Nitrendipine.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Nitrendipine.Approved
BoceprevirThe metabolism of Nitrendipine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Nitrendipine.Approved, Investigational
BosentanThe serum concentration of Nitrendipine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Nitrendipine.Approved
BQ-123Nitrendipine may increase the hypotensive activities of BQ-123.Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nitrendipine.Approved, Investigational
BretyliumNitrendipine may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Nitrendipine.Approved, Investigational
BromfenacThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of hypotension can be increased when Bromocriptine is combined with Nitrendipine.Approved, Investigational
BromperidolThe serum concentration of Bromperidol can be increased when it is combined with Nitrendipine.Approved, Investigational
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Nitrendipine.Investigational
BufexamacThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Bufexamac.Approved, Experimental
BumadizoneThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Bumetanide.Approved
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Nitrendipine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nitrendipine.Approved, Investigational
BupranololNitrendipine may increase the hypotensive activities of Bupranolol.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Nitrendipine.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Nitrendipine.Approved
CadralazineCadralazine may increase the hypotensive activities of Nitrendipine.Experimental
Calcium AcetateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Phosphate.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Nitrendipine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Nitrendipine.Approved
CandesartanNitrendipine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Nitrendipine.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Nitrendipine.Experimental
CaptoprilNitrendipine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Nitrendipine can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nitrendipine.Approved, Investigational
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Nitrendipine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Nitrendipine.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Nitrendipine.Withdrawn
CarprofenThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololNitrendipine may increase the hypotensive activities of Carteolol.Approved
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Nitrendipine.Approved, Investigational
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Nitrendipine.Approved, Investigational, Nutraceutical, Vet Approved
CelecoxibThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Nitrendipine.Approved, Investigational
CeritinibThe serum concentration of Nitrendipine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Nitrendipine.Approved, Withdrawn
Cerliponase alfaThe serum concentration of Cerliponase alfa can be increased when it is combined with Nitrendipine.Approved, Investigational
ChlorambucilThe serum concentration of Chlorambucil can be increased when it is combined with Nitrendipine.Approved
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Nitrendipine.Approved, Investigational, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Nitrendipine.Approved, Vet Approved
ChlorpromazineThe risk or severity of hypotension can be increased when Chlorpromazine is combined with Nitrendipine.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Nitrendipine.Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CicletanineNitrendipine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilNitrendipine may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nitrendipine.Approved, Investigational
CimetidineThe serum concentration of Nitrendipine can be increased when it is combined with Cimetidine.Approved, Investigational
CimicoxibThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Cimicoxib.Investigational
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Nitrendipine.Approved, Investigational
CisatracuriumNitrendipine may increase the neuromuscular blocking activities of Cisatracurium.Approved
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Nitrendipine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Nitrendipine.Approved
ClarithromycinThe metabolism of Nitrendipine can be decreased when combined with Clarithromycin.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Clevidipine.Approved, Investigational
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Nitrendipine.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Nitrendipine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nitrendipine.Approved, Investigational, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Nitrendipine.Approved
ClonixinThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Clonixin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nitrendipine.Approved
CloranololNitrendipine may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Nitrendipine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of hypotension can be increased when Clozapine is combined with Nitrendipine.Approved
CobicistatThe metabolism of Nitrendipine can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Nitrendipine.Approved, Investigational
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Nitrendipine.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Nitrendipine.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Nitrendipine.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Nitrendipine.Approved, Investigational
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Nitrendipine.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Nitrendipine.Approved
CurcuminThe metabolism of Nitrendipine can be decreased when combined with Curcumin.Approved, Investigational
CyclopenthiazideNitrendipine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Nitrendipine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Nitrendipine.Approved
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Nitrendipine.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Nitrendipine.Approved
DabrafenibThe serum concentration of Nitrendipine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Nitrendipine.Approved, Investigational
DanazolThe metabolism of Nitrendipine can be decreased when combined with Danazol.Approved
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Nitrendipine.Approved, Investigational, Withdrawn
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Nitrendipine.Approved
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Nitrendipine.Approved
DarunavirThe metabolism of Nitrendipine can be decreased when combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Nitrendipine.Approved
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Nitrendipine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Nitrendipine.Approved, Investigational
DeferasiroxThe serum concentration of Nitrendipine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilNitrendipine may increase the hypotensive activities of Delapril.Investigational
DelavirdineThe metabolism of Nitrendipine can be decreased when combined with Delavirdine.Approved
DeserpidineNitrendipine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Nitrendipine.Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Nitrendipine.Approved, Investigational, Vet Approved
DexibuprofenThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Dexibuprofen.Approved, Investigational
DexketoprofenThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Dexketoprofen.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Dexmedetomidine.Approved, Vet Approved
DexniguldipineNitrendipine may increase the hypotensive activities of Dexniguldipine.Experimental
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Nitrendipine.Approved, Illicit, Investigational, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Nitrendipine.Approved
DiclofenacThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Diclofenamide.Approved, Investigational
DiethylnorspermineNitrendipine may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Nitrendipine.Approved, Investigational
DifenpiramideThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Difenpiramide.Experimental
DiflunisalThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Diflunisal.Approved, Investigational
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Nitrendipine.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nitrendipine.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
DihydroergotamineThe risk or severity of hypotension can be increased when Dihydroergotamine is combined with Nitrendipine.Approved, Investigational
DiltiazemThe metabolism of Nitrendipine can be decreased when combined with Diltiazem.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Dinutuximab.Approved, Investigational
DipyridamoleDipyridamole may increase the antihypertensive activities of Nitrendipine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Nitrendipine.Approved, Investigational
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Nitrendipine.Approved
DolutegravirThe serum concentration of Dolutegravir can be increased when it is combined with Nitrendipine.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Nitrendipine.Approved, Investigational, Vet Approved
DorzolamideDorzolamide may increase the hypotensive activities of Nitrendipine.Approved
DoxacuriumNitrendipine may increase the neuromuscular blocking activities of Doxacurium.Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Nitrendipine.Approved
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Nitrendipine.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Nitrendipine.Approved, Investigational
DoxycyclineThe metabolism of Nitrendipine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Nitrendipine.Approved
DroperidolThe risk or severity of hypotension can be increased when Droperidol is combined with Nitrendipine.Approved, Vet Approved
DroxicamThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Droxicam.Withdrawn
DuloxetineNitrendipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Nitrendipine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Nitrendipine.Approved
EfavirenzThe serum concentration of Nitrendipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Nitrendipine.Approved
EfonidipineNitrendipine may increase the hypotensive activities of Efonidipine.Approved, Investigational
ElagolixThe serum concentration of Elagolix can be increased when it is combined with Nitrendipine.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Nitrendipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Nitrendipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Nitrendipine.Approved, Vet Approved
EnalaprilatNitrendipine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Nitrendipine.Experimental
EnzalutamideThe serum concentration of Nitrendipine can be decreased when it is combined with Enzalutamide.Approved
EpanololNitrendipine may increase the hypotensive activities of Epanolol.Experimental
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Nitrendipine.Approved, Investigational
EpirizoleThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Eplerenone.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Nitrendipine.Approved
EprosartanEprosartan may increase the hypotensive activities of Nitrendipine.Approved
ErgotamineThe risk or severity of hypotension can be increased when Ergotamine is combined with Nitrendipine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Nitrendipine.Approved, Investigational
ErtugliflozinThe serum concentration of Ertugliflozin can be increased when it is combined with Nitrendipine.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Nitrendipine.Approved, Investigational, Vet Approved
EsatenololNitrendipine may increase the hypotensive activities of Esatenolol.Experimental
EsmololNitrendipine may increase the hypotensive activities of Esmolol.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Nitrendipine.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be increased when it is combined with Nitrendipine.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be increased when it is combined with Nitrendipine.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be increased when it is combined with Nitrendipine.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be increased when it is combined with Nitrendipine.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be increased when it is combined with Nitrendipine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Nitrendipine.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Nitrendipine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Etacrynic acid.Approved, Investigational
EthenzamideThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Nitrendipine.Approved
EtodolacThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Nitrendipine.Approved
EtoricoxibThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Nitrendipine can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Nitrendipine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Nitrendipine.Approved
FelbinacThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Felbinac.Experimental
FelodipineFelodipine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Nitrendipine.Approved
FenoprofenThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Fenoprofen.Approved
FentiazacThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Fentiazac.Experimental
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Nitrendipine.Experimental
FeprazoneThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Feprazone.Experimental
Ferulic acidNitrendipine may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Nitrendipine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Nitrendipine.Approved, Investigational
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Nitrendipine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nitrendipine.Approved, Investigational
FirocoxibThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Firocoxib.Experimental, Vet Approved
FloctafenineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Floctafenine.Approved, Withdrawn
Fluciclovine (18F)The serum concentration of Fluciclovine (18F) can be increased when it is combined with Nitrendipine.Approved
FluconazoleThe metabolism of Nitrendipine can be decreased when combined with Fluconazole.Approved, Investigational
FlunixinThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Flunoxaprofen.Experimental
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Nitrendipine.Approved, Investigational, Withdrawn
FlurbiprofenThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FluticasoneThe serum concentration of Fluticasone can be increased when it is combined with Nitrendipine.Approved, Experimental, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Nitrendipine.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Nitrendipine.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Nitrendipine.Experimental
FluvoxamineThe metabolism of Nitrendipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Nitrendipine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Nitrendipine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilFosinopril may increase the hypotensive activities of Nitrendipine.Approved
FosinoprilatNitrendipine may increase the hypotensive activities of Fosinoprilat.Experimental
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Nitrendipine.Approved, Investigational
FostamatinibFostamatinib may increase the antihypertensive activities of Nitrendipine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Nitrendipine.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Nitrendipine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GallamineNitrendipine may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideNitrendipine may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Nitrendipine.Approved, Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Nitrendipine.Approved, Investigational
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Nitrendipine.Approved, Investigational
Gramicidin DThe serum concentration of Gramicidin D can be increased when it is combined with Nitrendipine.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Nitrendipine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Nitrendipine.Approved, Investigational, Withdrawn
GuacetisalThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Nitrendipine.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Nitrendipine.Approved
GuanazodineNitrendipine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineNitrendipine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
GuanoclorNitrendipine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzNitrendipine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanNitrendipine may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Nitrendipine.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Nitrendipine.Experimental
HexamethoniumNitrendipine may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Nitrendipine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Nitrendipine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Nitrendipine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Nitrendipine.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Nitrendipine.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Nitrendipine.Approved, Investigational
HydroxyureaThe serum concentration of Hydroxyurea can be increased when it is combined with Nitrendipine.Approved
IbuprofenThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Ibuproxam.Withdrawn
IcosapentThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Icosapent.Approved, Nutraceutical
IdelalisibThe metabolism of Nitrendipine can be decreased when combined with Idelalisib.Approved
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Nitrendipine.Approved
IloprostIloprost may increase the hypotensive activities of Nitrendipine.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Nitrendipine.Approved
ImidaprilNitrendipine may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Imidazole salicylate.Experimental
ImipramineThe risk or severity of hypotension can be increased when Imipramine is combined with Nitrendipine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Nitrendipine.Approved
IndapamideIndapamide may increase the hypotensive activities of Nitrendipine.Approved
IndenololNitrendipine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Nitrendipine can be decreased when combined with Indinavir.Approved
IndobufenThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Nitrendipine.Withdrawn
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Nitrendipine.Approved, Investigational
IproniazidIproniazid may increase the hypotensive activities of Nitrendipine.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Nitrendipine.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Nitrendipine.Approved, Investigational
IsavuconazoleThe serum concentration of Nitrendipine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Nitrendipine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Nitrendipine.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Nitrendipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Nitrendipine.Approved, Vet Approved
IsoniazidThe metabolism of Nitrendipine can be decreased when combined with Isoniazid.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Isosorbide Mononitrate.Approved
IsoxicamThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
ItraconazoleThe metabolism of Nitrendipine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Nitrendipine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Nitrendipine.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Ivosidenib can be increased when it is combined with Nitrendipine.Approved, Investigational
KebuzoneThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Nitrendipine.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Nitrendipine.Approved
KetoconazoleThe metabolism of Nitrendipine can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Ketorolac.Approved
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Nitrendipine.Approved
LacidipineNitrendipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Nitrendipine.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Nitrendipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Nitrendipine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Nitrendipine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Nitrendipine.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Nitrendipine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Nitrendipine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Nitrendipine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Nitrendipine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
LetermovirThe serum concentration of Letermovir can be increased when it is combined with Nitrendipine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Nitrendipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nitrendipine.Approved, Investigational
LevodopaNitrendipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Nitrendipine.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Nitrendipine.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Nitrendipine.Approved, Investigational
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Nitrendipine.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Nitrendipine.Approved
LinezolidLinezolid may increase the hypotensive activities of Nitrendipine.Approved, Investigational
LinsidomineNitrendipine may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Nitrendipine.Approved, Investigational
LofexidineNitrendipine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Lonazolac.Experimental
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Nitrendipine.Approved
LopinavirThe metabolism of Nitrendipine can be decreased when combined with Lopinavir.Approved
LornoxicamThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Nitrendipine can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Nitrendipine.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Nitrendipine.Approved, Investigational
LoxoprofenThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Nitrendipine.Approved, Investigational
LuliconazoleThe serum concentration of Nitrendipine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Nitrendipine can be increased when combined with Lumacaftor.Approved
LumiracoxibThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Lumiracoxib.Approved, Investigational
LusutrombopagThe serum concentration of Lusutrombopag can be increased when it is combined with Nitrendipine.Approved, Investigational
MacitentanNitrendipine may increase the hypotensive activities of Macitentan.Approved
Magnesium carbonateThe therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Nitrendipine.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Nitrendipine.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Nitrendipine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Nitrendipine is combined with Magnesium oxide.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Nitrendipine.Experimental
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Nitrendipine is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Nitrendipine is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineNitrendipine may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Nitrendipine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Nitrendipine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Meclofenamic acidThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Mefenamic acid.Approved
MefloquineThe serum concentration of Mefloquine can be increased when it is combined with Nitrendipine.Approved, Investigational
MeloxicamThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MelphalanThe serum concentration of Melphalan can be increased when it is combined with Nitrendipine.Approved
MesalazineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Metamizole.Approved, Investigational, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Nitrendipine.Approved
MethoserpidineNitrendipine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Nitrendipine.Approved
MethotrimeprazineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Nitrendipine.Approved, Investigational
MethyclothiazideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Methyclothiazide.Approved
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Nitrendipine.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Nitrendipine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Nitrendipine.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nitrendipine.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Nitrendipine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Nitrendipine.Approved, Vet Approved
MetipranololNitrendipine may increase the hypotensive activities of Metipranolol.Approved
MetocurineNitrendipine may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideNitrendipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetolazoneMetolazone may increase the hypotensive activities of Nitrendipine.Approved
MetoprololMetoprolol may increase the hypotensive activities of Nitrendipine.Approved, Investigational
MetyrosineNitrendipine may increase the hypotensive activities of Metyrosine.Approved
MibefradilThe metabolism of Nitrendipine can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Nitrendipine can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MifepristoneThe serum concentration of Nitrendipine can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Nitrendipine.Approved
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Nitrendipine.Approved, Vet Approved
MinoxidilMinoxidil may increase the hypotensive activities of Nitrendipine.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Nitrendipine.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Nitrendipine.Investigational
MitomycinThe serum concentration of Mitomycin can be increased when it is combined with Nitrendipine.Approved
MitotaneThe serum concentration of Nitrendipine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Nitrendipine.Approved, Investigational
MivacuriumNitrendipine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Nitrendipine.Approved, Investigational
ModafinilThe serum concentration of Nitrendipine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Nitrendipine.Approved
MofebutazoneThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
MorniflumateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Morniflumate.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Nitrendipine.Approved, Investigational
MoxidectinThe serum concentration of Moxidectin can be increased when it is combined with Nitrendipine.Approved, Investigational, Vet Approved
MoxonidineMoxonidine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
MuzolimineNitrendipine may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Nitrendipine.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Nitrendipine.Approved, Investigational
NabumetoneThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Nitrendipine.Approved
NafcillinThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftopidilNitrendipine may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Nitrendipine.Approved
NaloxoneThe metabolism of Nitrendipine can be decreased when combined with Naloxone.Approved, Vet Approved
NaproxenThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Naproxen.Approved, Vet Approved
NebivololNitrendipine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of hypotension can be increased when Nefazodone is combined with Nitrendipine.Approved, Withdrawn
NelfinavirThe metabolism of Nitrendipine can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Neostigmine can be increased when it is combined with Nitrendipine.Approved, Vet Approved
NepafenacThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Nepafenac.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Nitrendipine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Nitrendipine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Nitrendipine.Withdrawn
NicardipineThe risk or severity of hypotension can be increased when Nicardipine is combined with Nitrendipine.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Nitrendipine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Nitrendipine.Approved
NifenazoneThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Nitrendipine.Experimental
NilotinibThe metabolism of Nitrendipine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineNitrendipine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Nitrendipine.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Nitric Oxide.Approved
NitroaspirinThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitrendipine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Nitrous acid.Approved, Investigational
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Nitrendipine.Approved
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Nitrendipine.Approved
NS-398The therapeutic efficacy of Nitrendipine can be decreased when used in combination with NS-398.Experimental
ObinutuzumabNitrendipine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Nitrendipine.Withdrawn
OctreotideThe serum concentration of Octreotide can be increased when it is combined with Nitrendipine.Approved, Investigational
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Nitrendipine.Investigational
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Nitrendipine.Approved, Investigational
OlaparibThe metabolism of Nitrendipine can be decreased when combined with Olaparib.Approved
OlmesartanOlmesartan may increase the hypotensive activities of Nitrendipine.Approved, Investigational
OlsalazineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Olsalazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Nitrendipine.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Nitrendipine.Approved, Investigational
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Nitrendipine.Approved, Investigational, Vet Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Nitrendipine.Experimental
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Nitrendipine.Approved
OxaprozinThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Oxaprozin.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Nitrendipine.Approved
OxprenololNitrendipine may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Nitrendipine.Investigational, Withdrawn
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Nitrendipine.Approved, Vet Approved
PalbociclibThe serum concentration of Nitrendipine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Nitrendipine.Approved
PancuroniumNitrendipine may increase the neuromuscular blocking activities of Pancuronium.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Nitrendipine.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Nitrendipine.Approved
PapaverineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Papaverine.Approved, Investigational
ParecoxibThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Nitrendipine.Approved
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Nitrendipine.Approved, Investigational
Patent BlueThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Patent Blue.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Nitrendipine.Approved
PenbutololNitrendipine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Nitrendipine.Experimental
PentazocineThe serum concentration of Pentazocine can be increased when it is combined with Nitrendipine.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Nitrendipine.Approved, Investigational, Vet Approved
PentoliniumNitrendipine may increase the hypotensive activities of Pentolinium.Approved
PerindoprilPerindopril may increase the hypotensive activities of Nitrendipine.Approved
PerindoprilatNitrendipine may increase the hypotensive activities of Perindoprilat.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Nitrendipine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Nitrendipine.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Nitrendipine.Approved, Investigational
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Nitrendipine.Approved, Withdrawn
PhenothiazineThe serum concentration of Phenothiazine can be increased when it is combined with Nitrendipine.Vet Approved
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Nitrendipine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Nitrendipine.Withdrawn
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Nitrendipine.Approved
PhenylbutazoneThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Nitrendipine.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Nitrendipine.Approved, Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Nitrendipine.Approved
PinacidilPinacidil may increase the hypotensive activities of Nitrendipine.Approved
PindololNitrendipine may increase the hypotensive activities of Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Pipamperone.Approved, Investigational
PipecuroniumNitrendipine may increase the neuromuscular blocking activities of Pipecuronium.Approved
PirlindolePirlindole may increase the hypotensive activities of Nitrendipine.Approved
PiroxicamThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Pirprofen.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Nitrendipine.Approved
PitolisantThe serum concentration of Nitrendipine can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Nitrendipine.Withdrawn
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Nitrendipine.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Nitrendipine.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Nitrendipine.Approved, Investigational
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Nitrendipine.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Nitrendipine.Approved, Vet Approved
PolythiazideNitrendipine may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Nitrendipine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Nitrendipine.Approved, Investigational
PosaconazoleThe metabolism of Nitrendipine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Nitrendipine.Approved, Investigational
PractololNitrendipine may increase the hypotensive activities of Practolol.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Pramipexole.Approved, Investigational
PranoprofenThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Nitrendipine.Approved
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Nitrendipine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Nitrendipine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Nitrendipine.Approved, Vet Approved
PrimidonePrimidone may increase the hypotensive activities of Nitrendipine.Approved, Vet Approved
ProglumetacinThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Proglumetacin.Experimental
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Nitrendipine.Approved, Vet Approved
PropacetamolThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Propacetamol.Approved, Investigational
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Nitrendipine.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Nitrendipine.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Nitrendipine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Nitrendipine.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Proquazone.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Nitrendipine.Approved
QuetiapineThe risk or severity of hypotension can be increased when Quetiapine is combined with Nitrendipine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Nitrendipine.Approved, Investigational
QuinaprilatNitrendipine may increase the hypotensive activities of Quinaprilat.Experimental
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Nitrendipine.Approved, Investigational
QuinineThe metabolism of Nitrendipine can be increased when combined with Quinine.Approved
RamiprilRamipril may increase the hypotensive activities of Nitrendipine.Approved
RamiprilatNitrendipine may increase the hypotensive activities of Ramiprilat.Experimental
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Nitrendipine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Nitrendipine.Approved, Investigational
RapacuroniumNitrendipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Nitrendipine.Approved
RavuconazoleThe therapeutic efficacy of Ravuconazole can be increased when used in combination with Nitrendipine.Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Nitrendipine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Nitrendipine.Approved
RescinnamineNitrendipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Nitrendipine.Approved, Investigational
Rhodamine 6GThe serum concentration of Rhodamine 6G can be increased when it is combined with Nitrendipine.Experimental
RifampicinThe metabolism of Nitrendipine can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Nitrendipine can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Nitrendipine can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Nitrendipine.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
RimexoloneThe metabolism of Nitrendipine can be increased when combined with Rimexolone.Approved
RiociguatNitrendipine may increase the hypotensive activities of Riociguat.Approved
RisperidoneNitrendipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Nitrendipine can be decreased when combined with Ritonavir.Approved, Investigational
RituximabNitrendipine may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Nitrendipine.Approved
RobenacoxibThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Robenacoxib.Experimental, Vet Approved
RocuroniumNitrendipine may increase the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Rofecoxib.Approved, Investigational, Withdrawn
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Nitrendipine.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Rotigotine.Approved
RucaparibThe serum concentration of Rucaparib can be increased when it is combined with Nitrendipine.Approved, Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Sacubitril.Approved
SafinamideSafinamide may increase the hypotensive activities of Nitrendipine.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Nitrendipine.Withdrawn
SalicylamideThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Salsalate.Approved
SaprisartanNitrendipine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Nitrendipine can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Sarilumab.Approved, Investigational
SC-236The therapeutic efficacy of Nitrendipine can be decreased when used in combination with SC-236.Experimental, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Nitrendipine.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Nitrendipine.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Nitrendipine.Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Nitrendipine.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Nitrendipine.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Nitrendipine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Nitrendipine.Approved
SiltuximabThe serum concentration of Nitrendipine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Nitrendipine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Nitrendipine.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Nitrendipine.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Nitrendipine.Approved, Investigational
SitaxentanNitrendipine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Nitrendipine.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Nitrendipine.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Nitrendipine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Nitrendipine.Approved
SomatostatinThe serum concentration of Somatostatin can be increased when it is combined with Nitrendipine.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Nitrendipine.Approved, Investigational
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Nitrendipine.Approved
SotalolThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Nitrendipine.Approved, Investigational
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Nitrendipine.Experimental
SpiraprilNitrendipine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Nitrendipine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneThe serum concentration of Stanolone can be increased when it is combined with Nitrendipine.Illicit, Investigational
Stanolone acetateThe serum concentration of Stanolone acetate can be increased when it is combined with Nitrendipine.Experimental
StiripentolThe serum concentration of Nitrendipine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Sufentanil.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Nitrendipine.Approved
SulfasalazineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Sulindac.Approved, Investigational
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Nitrendipine.Approved, Investigational
SunitinibThe serum concentration of Sunitinib can be increased when it is combined with Nitrendipine.Approved, Investigational
SuprofenThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Suxibuzone.Experimental
TacrineThe serum concentration of Tacrine can be increased when it is combined with Nitrendipine.Investigational, Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Nitrendipine.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Nitrendipine.Approved, Investigational
TalinololThe serum concentration of Talinolol can be increased when it is combined with Nitrendipine.Investigational
TalniflumateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Talniflumate.Approved
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Nitrendipine.Approved
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Nitrendipine.Approved, Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Nitrendipine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Nitrendipine.Approved, Investigational
TegaserodThe therapeutic efficacy of Tegaserod can be decreased when used in combination with Nitrendipine.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Nitrendipine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Nitrendipine can be decreased when combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Nitrendipine.Approved, Investigational
TemocaprilNitrendipine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Nitrendipine.Approved
TenidapThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Tenidap.Experimental
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Nitrendipine.Approved
TenoxicamThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Nitrendipine.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Nitrendipine.Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Nitrendipine.Approved, Withdrawn
Testosterone propionateThe serum concentration of Testosterone propionate can be increased when it is combined with Nitrendipine.Approved, Investigational, Vet Approved, Withdrawn
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Nitrendipine.Approved, Vet Approved
TetrahydropalmatineNitrendipine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the antihypertensive activities of Nitrendipine.Approved
ThiamylalThiamylal may increase the hypotensive activities of Nitrendipine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Nitrendipine.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Nitrendipine.Approved
ThioridazineThe risk or severity of hypotension can be increased when Thioridazine is combined with Nitrendipine.Approved, Withdrawn
Tiaprofenic acidThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Tiaprofenic acid.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Nitrendipine.Approved
TicrynafenNitrendipine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe serum concentration of Timolol can be increased when it is combined with Nitrendipine.Approved
TinoridineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Tinoridine.Investigational
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Nitrendipine.Approved
TipranavirThe metabolism of Nitrendipine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Tizanidine.Approved, Investigational
TocilizumabThe serum concentration of Nitrendipine can be decreased when it is combined with Tocilizumab.Approved
TocopherylquinoneNitrendipine may increase the hypotensive activities of Tocopherylquinone.Experimental, Investigational
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Nitrendipine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
TolmetinThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Tolmetin.Approved
TolonidineNitrendipine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Nitrendipine.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Nitrendipine.Approved
TopiramateThe serum concentration of Topiramate can be increased when it is combined with Nitrendipine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Nitrendipine.Approved, Investigational
TorasemideTorasemide may increase the hypotensive activities of Nitrendipine.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Nitrendipine.Approved
TranylcypromineTranylcypromine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Nitrendipine.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Nitrendipine.Approved
TrazodoneThe risk or severity of hypotension can be increased when Trazodone is combined with Nitrendipine.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Nitrendipine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Triamterene.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Nitrendipine.Approved, Vet Approved
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Nitrendipine.Approved, Investigational
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Nitrendipine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Nitrendipine.Approved, Investigational
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Nitrendipine.Approved
Trolamine salicylateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Trolamine salicylate.Approved
TroleandomycinThe metabolism of Nitrendipine can be decreased when combined with Troleandomycin.Approved
TubocurarineNitrendipine may increase the neuromuscular blocking activities of Tubocurarine.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Nitrendipine.Approved, Investigational, Nutraceutical
UdenafilUdenafil may increase the antihypertensive activities of Nitrendipine.Approved, Investigational
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Nitrendipine.Approved
UnoprostoneNitrendipine may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Nitrendipine.Investigational
Ursodeoxycholic acidUrsodeoxycholic acid can cause a decrease in the absorption of Nitrendipine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ValdecoxibThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Valdecoxib.Approved, Investigational, Withdrawn
ValinomycinThe serum concentration of Valinomycin can be increased when it is combined with Nitrendipine.Experimental
ValsartanValsartan may increase the hypotensive activities of Nitrendipine.Approved, Investigational
ValspodarThe serum concentration of Valspodar can be increased when it is combined with Nitrendipine.Investigational
VardenafilVardenafil may increase the antihypertensive activities of Nitrendipine.Approved
VecuroniumNitrendipine may increase the neuromuscular blocking activities of Vecuronium.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Nitrendipine.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Nitrendipine.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Nitrendipine.Approved, Investigational
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Nitrendipine.Approved
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Nitrendipine.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Nitrendipine.Approved
VincamineNitrendipine may increase the hypotensive activities of Vincamine.Experimental
VincristineThe excretion of Vincristine can be decreased when combined with Nitrendipine.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be increased when it is combined with Nitrendipine.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Nitrendipine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Nitrendipine.Approved, Investigational
VoriconazoleThe metabolism of Nitrendipine can be decreased when combined with Voriconazole.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Nitrendipine.Approved, Investigational
XipamideNitrendipine may increase the hypotensive activities of Xipamide.Experimental
YohimbineYohimbine may decrease the antihypertensive activities of Nitrendipine.Approved, Investigational, Vet Approved
ZaltoprofenThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Nitrendipine.Approved
ZiprasidoneThe risk or severity of hypotension can be increased when Ziprasidone is combined with Nitrendipine.Approved
ZofenoprilNitrendipine may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Zomepirac.Withdrawn
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Nitrendipine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Wolfgang Schmidt, Bernhard Streuff, Manfred Winter, "Preparation of solid medicament formulation containing nitrendipine." U.S. Patent US4724141, issued April, 1980.

US4724141
General References
Not Available
External Links
Human Metabolome Database
HMDB0015187
KEGG Drug
D00629
KEGG Compound
C07713
PubChem Compound
4507
PubChem Substance
46508817
ChemSpider
4351
BindingDB
50012016
ChEBI
7582
ChEMBL
CHEMBL475534
Therapeutic Targets Database
DAP001263
PharmGKB
PA146096020
IUPHAR
2334
Guide to Pharmacology
GtP Drug Page
Wikipedia
Nitrendipine
ATC Codes
C08CA08 — NitrendipineC09BB06 — Enalapril and nitrendipine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Unknown StatusTreatmentHigh Blood Pressure (Hypertension)1
4WithdrawnTreatmentChronic Kidney Disease (CKD) / High Blood Pressure (Hypertension)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)156-160 °CNot Available
water solubilityInsolubleNot Available
logP2.88MASUMATO,K ET AL. (1995)
Caco2 permeability-4.77ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0142 mg/mLALOGPS
logP3.21ALOGPS
logP2.17ChemAxon
logS-4.4ALOGPS
pKa (Strongest Basic)5.43ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area110.45 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity96.91 m3·mol-1ChemAxon
Polarizability36.25 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9536
Blood Brain Barrier-0.9549
Caco-2 permeable+0.7853
P-glycoprotein substrateSubstrate0.5265
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.8313
Renal organic cation transporterNon-inhibitor0.8984
CYP450 2C9 substrateNon-substrate0.8212
CYP450 2D6 substrateNon-substrate0.8931
CYP450 3A4 substrateSubstrate0.7266
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.8993
CYP450 3A4 inhibitorInhibitor0.8037
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9247
Ames testNon AMES toxic0.7334
CarcinogenicityNon-carcinogens0.5186
BiodegradationNot ready biodegradable0.9581
Rat acute toxicity2.3810 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8131
hERG inhibition (predictor II)Non-inhibitor0.9094
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0ab9-2539000000-3d9a9111a145f234fc24
MS/MS Spectrum - , positiveLC-MS/MSsplash10-016r-0159000000-7b0ccf9fb639868092f0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-016r-0159000000-4e10a6643ba97ab23a0f

Taxonomy

Description
This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Hydropyridines
Direct Parent
Dihydropyridinecarboxylic acids and derivatives
Alternative Parents
Nitrobenzenes / Nitroaromatic compounds / Dicarboxylic acids and derivatives / Vinylogous amides / Enoate esters / Methyl esters / Amino acids and derivatives / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Enamines
show 6 more
Substituents
Dihydropyridinecarboxylic acid derivative / Nitrobenzene / Nitroaromatic compound / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Benzenoid / Methyl ester / Enoate ester / Alpha,beta-unsaturated carboxylic ester / Vinylogous amide
show 23 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
C-nitro compound, ethyl ester, diester, dihydropyridine (CHEBI:7582)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1C
Uniprot ID
Q13936
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight
248974.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-...
Gene Name
CACNA2D1
Uniprot ID
P54289
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-1
Molecular Weight
124566.93 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB2
Uniprot ID
Q08289
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-2
Molecular Weight
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
This protein is a subunit of the dihydropyridine (DHP) sensitive calcium channel. Plays a role in excitation-contraction coupling. The skeletal muscle DHP-sensitive Ca(2+) channel may function only...
Gene Name
CACNG1
Uniprot ID
Q06432
Uniprot Name
Voltage-dependent calcium channel gamma-1 subunit
Molecular Weight
25028.105 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1D
Uniprot ID
Q01668
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1D
Molecular Weight
245138.75 Da
References
  1. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1S
Uniprot ID
Q13698
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1S
Molecular Weight
212348.1 Da
References
  1. Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-t...
Gene Name
CACNA2D2
Uniprot ID
Q9NY47
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-2
Molecular Weight
129816.095 Da
References
  1. Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1H
Uniprot ID
O95180
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1H
Molecular Weight
259160.2 Da
References
  1. Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674]
  2. Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K: Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci. 2002 Aug;16(3):159-65. [PubMed:12128170]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Pedersen JM, Matsson P, Bergstrom CA, Hoogstraate J, Noren A, LeCluyse EL, Artursson P: Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. doi: 10.1093/toxsci/kft197. Epub 2013 Sep 6. [PubMed:24014644]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:48